Transcriptional modulation of the PI3K/AKT/mTOR signaling pathway mediated by HPV16 E5, E6, and E7 oncogene expression in breast cancer.
What this study shows
In breast tumour tissue (48 of 92 patients with usable RNA), HPV16 oncogene expression was associated with higher PI3K and lower mTOR transcript levels. The design is correlational and measures mRNA only, so it does not show that the virus activates the mTOR pathway.
At a glance
| Evidence type | M Molecular — cells, biochemistry, structure Marked M because it is molecular or in-vitro work (model: Human (clinical samples, FFPE tissue)) rather than a whole-organism health-outcome study. That is often exactly where causal biology gets established -- the code says which system the finding was shown in, and nothing about how good the work is. |
| Study type | 5 - Mechanistic / In Vitro |
| Model system | Human (clinical samples, FFPE tissue) |
| Journal | Exploration of targeted anti-tumor therapy |
| Year | 2026 |
| Peer reviewed | Yes |
| Record last updated | 2026-10-01 |
| Source | DOI 10.37349/etat.2026.1002391 · PMID 42558973 · Free full text (PMC13439120) |
Extracted findings
These fields were extracted from the paper with AI assistance and have not been checked against the source. Read them as a pointer into the paper, not as curated claims; where they disagree with the curated summary above, the curated summary stands.
| Intervention | HPV16 oncogene expression |
| Target | PI3K/AKT/mTOR |
| Model | Human |
| Effect | HPV-positive tumours: PI3K mRNA higher, mTOR mRNA lower (association) |
In the Atlas
Related topics
More studies on this topic
- Anti-breast cancer effects of the Xingxiao Pill are associated with inhibition of the ErbB3/PI3K/AKT/mTOR pathway, modulation of amino acid metabolism, and promotion of apoptosis. (2026)
- Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer (BOLERO-2) (2012)
- EVERolimus effectiveness after proGREssion on ENdocrine therapy plus CDK4/6 inhibitor for ER-positive/HER2-negative advanced breast cancer: EVERGREEN study (2026)
- A bi-steric mTORC1-selective inhibitor overcomes drug resistance in breast cancer (2023)
Was this page useful?
Thank you. Your answer was counted anonymously.